Objective: Small quantities of normal saline are sometimes instilled into the endotracheal tube of intubated neonates, to assist with the removal of thick secretions and maintain patency of the endotracheal tube. However, saline is detrimental to the innate immune system of the upper airway mucosa, rapidly unfolding and inactivating antimicrobial peptides such as LL-37. We previously reported the preparation and feasibility testing of 'ETCare', a low-sodium, physiologically based solution for airway care, and we now report results of a randomized, masked, controlled, two-centered study testing ETCare vs sterile saline among 60 intubated NICU patients.
Objective: Small quantities of normal saline are sometimes instilled into the endotracheal tube of intubated neonates, to assist with the removal of thick secretions and maintain patency of the endotracheal tube. However, saline is detrimental to the innate immune system of the upper airway mucosa, rapidly unfolding and inactivating antimicrobial peptides such as LL-37. We previously reported the preparation and feasibility testing of 'ETCare', a low-sodium, physiologically based solution for airway care, and we now report results of a randomized, masked, controlled, two-centered study testing ETCare vs sterile saline among 60 intubated NICU patients.
Study Design: Sixty intubated NICU patients were randomized to having their airway care with ETCare vs saline. Three hypotheses were tested: (1) tolerance -patients will tolerate ETCare for airway care as well as they tolerate saline, (2) nosocomial infections -ETCare will result in fewer tracheal aspirates where organisms grow and fewer cases of nosocomial sepsis, and (3) chronic lung disuse -ETCare will result in fewer patients discharged home on supplemental O 2 .
Result: Thirty NICU patients with an endotracheal tube in place were randomized to receive their airway care with ETCare, and 30 to receive their care with saline. Only the pharmacist was aware of the randomization; the two solutions were visually indistinguishable and were dispensed in identical syringes. Tolerance of the solutions was similar. The ETCare recipients had trends toward fewer positive blood cultures (odds ratios (OR), 0.48; 95% confidence interval (CI), 0.13 to 1.68), and fewer discharges home on supplemental O 2 (OR, 0.43; 95% CI, 0.14 to 1.32; P ¼ 0.075).
Introduction
If a solution is instilled into the endotracheal tube of a neonate, preparatory to performing endotracheal suctioning, sterile saline is generally selected as that solution. [1] [2] [3] [4] [5] The practice of instilling saline as part of endotracheal tube suctioning is intended to enhance removal of thick secretions that can restrict gas flow through the endotracheal tube. Saline is also occasionally used to periodically clear the nasal passages of neonates on nasal continuous positive airway pressure. 6 One problem with using saline for periodic upper airway care in a neonate is that high concentrations of sodium and chloride inactivate natural antimicrobial properties of airway secretions. [7] [8] [9] [10] [11] [12] [13] Tracheal secretions, nasal secretions and saliva all have very low concentrations of sodium and chloride. Moreover, those secretions contain potent natural antibacterial substances that are inhibited by saline. One such substance is LL-37, a 37-amino-acid peptide, with widespread antimicrobial properties. [14] [15] [16] [17] Saline induces a conformational change in LL-37, which completely inactivates its antimicrobial capacity. Thus, mixing saline with tracheal secretions, nasal secretions or saliva damages the innate antimicrobial properties of those secretions. 7 We speculated that when a solution is deemed necessary for airway suctioning of an NICU patient, a solution patterned after the constituents of natural unstimulated saliva of neonates would be more physiological and less damaging than saline. We proposed a prototype solution and conducted a preliminary feasibility study, using the test solution for airway care of 10 intubated newborn infants. 18 We found that our prototype solution (ETCare) was indeed feasible to administer, with no obvious intolerance compared with the standard solution (normal saline). 18 As a next step, we conducted the present study among 60 intubated neonates. The purpose of the study was to obtain information on the safety and efficacy of the new solution (ETCare) vs the standard solution (normal saline) using a randomized, masked design. We judged that such a study was needed to provide data for the sample size calculations required in designing a future phase III trial.
Methods

Hypothesis and study design
We developed three hypotheses. First (tolerance), the test solution will be tolerated as well as saline. Second (nosocomial infections), the test solution will result in fewer tracheal aspirates where organisms are recovered, and fewer episodes of nosocomial sepsis. Third (chronic lung disease), the test solution will result in fewer patients requiring supplemental O 2 at discharge home.
The solution to be used for all upper airway care of study patients was delivered each day from the research pharmacy to the bedside in eight 3 ml syringes. The airway care solution was to be used any time a liquid was deemed necessary for suctioning of the endotracheal tube or nares, moistening the mouth or diluting aerosol treatments. The two airway care solutions tested (ETCare and normal saline) were visually indistinguishable. Tracheal aspirates were obtained for culture in accordance with a uniform policy (Supplementary Appendix 1). Any use of the airway care study solution in the trachea, nose or mouth was to be done according to the uniform guidelines (Supplementary Appendix 2).
Study participants
To be eligible for participation, a patient had to be in the NICU of either McKay-Dee Hospital (Ogden, UT, USA) or LDS Hospital (Salt Lake City, UT, USA) and less than 24 h old at the time of study entry, with an endotracheal tube in place, and not already enrolled in a conflicting research study. The patient also had to be declared, by attestation of the attending neonatologist, as likely to have an endotracheal tube in place for at least the next 48 h. Potential study patients were ineligible if they had what the attending neonatologist judged to be a 'lethal' congenital abnormality. Patients were to be considered 'off study' if the parents withdrew consent before the study was complete. The Intermountain Healthcare Institutional Review Board approved the study and the informed consent document was signed by the parents of all participating subjects.
Sample size and randomization A sample size could not be calculated using standard approaches, because data did not exist for estimating group differences and data distribution. Therefore, a convenience sample was selected (n ¼ 60) on the basis of our prediction that this number of patients could be studied in about 1 year. We anticipated that the data generated from this trial would enable sample size calculations for a subsequent phase III trial.
Once informed consent was obtained from the parents, the pharmacy was notified and the subject was randomized by the research pharmacist, using a random number table, to either the ETCare group or to the saline group. To avoid maldistribution, by chance, with a preponderance of smaller subjects in one study group, the randomization was blocked into 'cells' on the basis of birth weight, as follows: birth weight <1000 g, 20 with equal numbers assigned to each group; birth weight 1000 to 1500 g, 10 to 15 with equal numbers assigned to each group; birth weight >1500 g, 5 to 10 with equal numbers assigned to each group. The randomization was performed at both hospitals, coordinated by the research pharmacy department. Fewer patients were randomized into the heaver birth weight group and more into the middle group, on the basis that fewer of the large neonates were anticipated to require endotracheal intubation for prolonged period of time.
Preparation and distribution of the airway care solutions The constituents of infant and adult saliva [18] [19] [20] are shown in Table 1 , along with the constituents of normal saline and ETCare. The precise composition of ETCare is as follows: Na 7.8 mEq/l, K 24.5 mEq/l, Ca 3.67 mEq/l, Mg 1.2 mEq/l, Cl 36.3 mEq/l, PO 4 3 mEq/l, SO 4 1.2 mEq/l and albumin 1940 mg/l. A patent from Intermountain Healthcare, for ETCare, is pending in the United States Patent and Trademark Office.
ETCare was compounded sterilely by the research pharmacy staff using the hospital total parenteral nutrition equipment. Every 24 h, the pharmacy sent 3 ml syringes of the correct solution (ETCare or sterile, pyrogen-free, 0.9% sodium chloride) to the Airway care of intubated NICU patients RD Christensen et al NICU to be used for each specific study patient's airway care. These syringes were to be used for all periodic suctioning of the ET tube, and also for the occasional suction or cleaning of the nose and/or mouth as deemed needed by the bedside nurse and respiratory therapist in connection with the guidelines (Supplementary Appendix 1 and 2). The syringes were labeled, 'AIRWAY CARE STUDY SOLUTION'. The ETCare and 0.9% saline were visually indistinguishable, and only the pharmacy was aware which solution each patient was receiving. When each study patient no longer required any liquid for airway care (because he/she was extubated, had no nasal cannula and needed no nasal or oral care) the pharmacist did not send any additional airway care study solution to the bedside.
Study data collection
Study data related to potential intolerance of the solution were kept in a bedside flow sheet, using checklists and comment sections to provide information about feasibility and immediate tolerance of the solution. Study binders were used to collect data on tracheal aspirates, blood cultures obtained, duration of mechanical ventilation and requirements for supplemental O 2 at the time of discharge home. Individuals collecting the study specimens, culturing tracheal aspirates or blood, or recording study data, were unaware of the randomization. Similarly, all caregivers were unaware of the randomization; these included the respiratory therapists, bedside nurses, nurse practitioners, study nurses and neonatologists.
A consistent approach to obtaining tracheal aspirates (Supplementary Appendix 1) and blood cultures were employed among the study subjects. Briefly, blood cultures were obtained using two separate drawing sites, including an indwelling line if one was present, plus one peripheral blood site. Cultures were reported as positive if both blood specimens were positive for the same organism; unless only one culture could be obtained, in which case that single positive specimen followed by at least 7 days of antibiotic administration was deemed sufficient to categorize it as a positive culture. Blood cultures were obtained on all 60 patients upon initial admission to the NICU, but those cultures were not included in the study analysis, because the study focus was nosocomial infections. Tracheal aspirate cultures were reported to be positive if the microbiology laboratory reported the growth of any organism.
Statistical considerations
Data were entered into Microsoft Excel 2003 and imported into SPSS 14.0 for Windows (Chicago, IL, USA) for analysis. Descriptive statistics were calculated using standard methods. Comparisons between infants receiving ETCare vs saline were conducted using independent samples t-tests for continuous variables and Fisher's exact tests for dichotomous variables. Where parametric assumptions for continuous measures were not met, the permutation test on medians was used. All tests were two-sided; an a of <0.05 was considered significant.
Results
During the period June 2005 through December 2006, the families of 64 eligible NICU patients were contacted to inquire whether they were interested in learning about the airway care study. Sixty of the 64 gave written consent for their neonate to participate. All 60 who had given consent were enrolled in the study. Twenty were enrolled in the <1000 g birth weight cell (n ¼ 10 in each group); 26 were enrolled in the 1000 to 1500 g birth weight cell (13 in each group); and 14 were enrolled in the >1500 g birth weight cell (seven in each group).
Three patients who began the study died. They were not replaced by enrolling three additional patients. These three included a 685-g boy, 27-weeks gestation, donor of a twin-twin transfusion (randomized to the ETCare group) delivered after fetal demise of the recipient twin. The patient had anuria, and support was withdrawn on day 7. The second death (randomized to the saline group) was a 530-g boy, 22 weeks 6 days gestation, where support was withdrawn on day 5 because of severe bilateral intraventricular hemorrhages and respiratory failure. The third death (randomized to the ETCare group) was a 580-g boy, 23 weeks 6 days gestation, where support was withdrawn on day 8 because of persistent acidosis and bilateral severe intraventricular hemorrhages. In keeping with an intent-to-treat design, data from all 60 patients were considered in the demographic comparisons, and in testing tolerance of the solution. However, to test the hypotheses related to the outcomes of infections and supplemental O 2 at discharge, the outcome data were 'right censored' due to the deaths. Thus, only the 57 survivors were considered in those analyses.
No study subject had parental consent withdrawn after the study began. However, four (two in each group) were eventually transferred to the children's hospital for management. Three were transferred while still intubated and on study. Two of these (both in the ETCare group) had pneumoperitoneum discovered while being treated with indomethacin and hydrocortisone simultaneously. In both, it was determined at laparotomy to be an isolated ileal perforation. The transfers occurred on days 5 and 7. The third transfer (saline group) was on day 8, for necrotizing enterocolitis requiring bowel resection. The fourth transfer (saline group) was following extubation, on day 16, for evaluation of ventriculoperitoneal shut placement because of posthemorrhagic hydrocephalus. Outcomes of the four transferred patients were tracked and are included among the 57 survivors.
No significant differences were apparent between the group of 30 randomized to receive ETCare vs the group of 30 randomized to receive saline, in birth weight, gestational age, race, 1-and 5-min Apgar scores, or percent inborn vs outborn (Table 2) . However, a trend toward more males was observed in the saline group (P ¼ 0.058). The first administration of the airway care solution averaged 19 or 20 h of life in both groups. This reflected the time required after delivery to determine eligibility, conduct meetings with the parents, obtain consent, have the pharmacy randomize the patient and dispense the airway care solution to the bedside, and administer the first dose of the study solution when airway suctioning was deemed necessary, according to the study protocol (Supplementary Appendix 1) . Any airway care solution used before study entry was with saline. All 30 patients randomized to the ETCare group received endotracheal instillation of saline at least once before study entry.
The respiratory therapists and bedside nurses performing the airway care (periodically instilling the study solution and suctioning the trachea or nose) ascribed no intolerance to either solution. No differences were observed between the ETCare group and the saline group, in mortality rate, development of necrotizing enterocolitis, or days on mechanical ventilation (Table 2) . When the survivors in all three birth weight groups were considered together, no difference was identified in culture positive tracheal aspirates (OR, 0.91; 95% CI, 0.50 to 1.60), but trends were seen toward fewer positive blood cultures (OR, 0.48; 95% CI, 0.13 to 1.68) and fewer discharged home on supplemental O 2 (OR, 0.43; 95% CI, 0.14 to 1.32; P ¼ 0.075; Tables 3 and 4) . Table 4 displays the study outcomes, listed according to birth weight group. The relatively small numbers in each of these Patients where supplemental O 2 , by nasal cannula, was set up at home after hospital discharge/patients discharged home. The final columns show supplemental oxygen at discharge home. Each is shown for the ETCare and the saline recipients, separated according to birth weight category.
Airway care of intubated NICU patients RD Christensen et al subgroups precluded extensive formal data analysis. The five episodes of nosocomial sepsis in the ETCare group were with the following organisms; coagulase-negative staphylococcus (n ¼ 4), Enterobacter cloacae (n ¼ 1). The nine episodes of nosocomial infection in the normal saline group were with the following organisms; Candida albicans (n ¼ 1), Staphylococcus aureus (n ¼ 1) and coagulase-negative staphylococcus (n ¼ 7). One possible difference, noted when the data were displayed according to birth weight category ( Table 4 ), was that more evaluations for nosocomial sepsis were performed among the >1500 g neonates treated with saline. Specifically, six of the seven patients had a septic workup, compared with no septic workup performed among the seven ETCare recipients, (P ¼ 0.002).
Discussion
It is likely that the practice of instilling saline into the upper airways of NICU patients reduces their innate airway mucosal immune capacity, and unwittingly contributes to the high incidence of upper airway infections. [7] [8] [9] [10] [11] Many nosocomial infections in the NICU are with organisms that are of very low virulence in healthy adults, such as C. albicans and coagulasenegative staphylococcus. 21 A low IgG concentration is one factor predisposing preterm neonates to these infections, 22 and disruption of the mucosal barrier by the presence of tubes in the trachea, nose or mouth is likely another predisposing factor. Caregivers might further weaken local microbial defenses by the repeated instillation of saline into the upper airways.
Natural antimicrobial substances in saliva inhibit colonization of the mouth by C. albicans. 23 In ill neonates, oral candidiasis may be a step in the pathogenesis of systemic candidiasis, a condition with a high mortality rate. 24 A Cochrane Review by Austin and Darlow 25 indicates that there is insufficient evidence to support the use of prophylactic oral antifungal agents in very low birth weight infants to reduce oral candida. They suggest that reducing oral candida among ill neonates is worthwhile, but that additional studies are needed to determine how this can be accomplished. Perhaps one approach would involve finding ways to supplement innate mucosal oral and airway immunity, rather than damaging it by repeated saline instillations.
During endotracheal tube suctioning, the proper quantity of solution instilled into the tube is a matter of discussion and study.
1-4 Kinloch 3 recently suggested not instilling any saline into the endotracheal tube preceding suctioning. Indeed, 'dry suctioning' may now be a more common practice than that in the past, but it seems that most neonates intubated for several days have at least occasional use of liquid instillation to facilitate suctioning of the trachea or nasal passages. 18 On the basis of the preliminary findings of this study and our pilot trial, we conclude that when a solution for airway care is to be used in a NICU patient, ETCare is tolerated as well as saline. However, whether or not ETCare is better than saline, in terms of fewer infectious complications and less chronic lung disease, awaits definitive studies. We saw promising trends in the present data, but we realize that there are several pitfalls in attempting to extrapolate these trends into conclusions. For instance, the chance-occurrence that more male patients were assigned to the saline group might have contributed to the less favorable outcomes in that group. In addition, we realize that our formulation would probably be improved considerably by adding recombinant human LL-37 26, 27 and/or other natural antimicrobial substances that contribute to the innate immunity of airway secretions. 12, 13 Also, since nosocomial infections and chronic lung disease are surely of multifactorial pathogenesis, it is unlikely that any one new treatment would eliminate those adverse outcomes. ET aspirate cultures present difficulties, both in clinical interpretation and in the clinical research setting. Clearly, this is also a limitation of the present studies, in which we included all organisms if the microbiology laboratory reported these in the medical record. Perhaps some positive ET aspirate cultures are meaningful, particularly those obtained immediately after placement of a new sterile ET tube. Perhaps other cultures are not helpful, as they can reflect colonization of the in-line suctioning apparatus rather than the trachea or bronchi.
Most patients in this study (72% of the saline recipients and 52% of the ETCare recipients) were discharged home on supplemental oxygen. This might appear to be an inordinately high proportion of patients, but this is within the usual practice at our altitude (both hospitals are about 4800 ft above sea level). Certainly, any advance that reduced the need for supplemental O 2 at discharge would be particularly useful for the high-altitude centers. Despite these pitfalls, unresolved issues and the inconclusive nature of this early study, we interpret the findings as encouraging toward proceeding with a larger study and with improvements in the ETCare formulation. Specifically, we are proceeding with plans to include recombinant LL-37 in the ETCare formulation and to conduct multicentered trials where ETCare vs saline are tested in a double-masked, prospective, randomized fashion.
